Drug intelligence / Profile preview

carmustine + O6-benzylguanine

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

Carmustine + O6-benzylguanine is a combination therapy consisting of the alkylnitrosourea carmustine (BCNU) and the O6-alkylguanine-DNA alkyltransferase (AGT) inhibitor O6-benzylguanine. O6-benzylguanine works by inhibiting AGT through suicide inactivation, thereby preventing the repair of DNA damage caused by carmustine. This combination was developed to overcome resistance to nitrosourea therapy in malignant gliomas and other cancers. The maximum tolerated dose of carmustine when combined with O6-benzylguanine at 100 mg/m² was determined to be 40 mg/m² administered at 6-week intervals.

Other names: BCNU + O6-BG

Targets

DNAAGT (O6-methylguanine-DNA methyltransferase)

Beyond the preview

Go deeper on carmustine + O6-benzylguanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carmustine + O6-benzylguanine.

Explore the full profile